Later on, biologics were developed to target specific inflammatory cytokines involved in IBD, like TNFα, p40 subunit of IL-12 and IL-23, and to block lymphocyte recruitment like α4β7 integrin antibody. Here, TNF is linked to inflammatory bowel disease.